/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical pharmacokinetic study (PK.
STOCKHOLM, Dec. 8, 2021 /PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical pharmacokinetic study (PK study) with
/PRNewswire/ "We have now several clinics activated in the phase III study CONCLUDE and look forward to enrol the first patient in the near term", says.
/PRNewswire/ "We have now several clinics activated in the phase III study CONCLUDE and look forward to enrol the first patient in the near term", says.
Ready to initiate patient recruitment in phase III study CONCLUDE STOCKHOLM, Nov. 24, 2021 /PRNewswire/ "We have now several clinics activated in the phase III study CONCLUDE and look